Tolerance of high-dose coenzyme Q10 in ALS

Study Purpose:

An open-label dose-escalation trial was performed to assess the safety and tolerability of high doses of coenzyme Q10 (CoQ10) in ALS. CoQ10, a cofactor in mitochondrial electron transfer, may improve the mitochondrial dysfunction in ALS. In this study, CoQ10 was safe and well tolerated in 31 subjects treated with doses as high as 3,000 mg/day for 8 months.

Disease:

Amyotrophic Lateral Sclerosis (ALS), Familial ALS, Sporadic ALS

Study Type:

Interventional Trial

Study Category:

Drug Trial

Study Status:

Not enrolling

Phase:

Study Chair(s)/Principal Investigator(s):

Merit Cudkowicz, Massachusetts General Hospital

Clinicaltrials.gov ID (11 digit #):

Neals Affiliated?

Yes

Coordinating Center Contact Information

.(JavaScript must be enabled to view this email address)
.(JavaScript must be enabled to view this email address)

Full Study Summary:

Study Sponsor:

Participant Duration:

Estimated Enrollment:

Estimated Study Start Date:

06/01/2001

Estimated Study Completion Date:

05/31/2003

Posting Last Modified Date:

05/09/2019

Date Study Added to alsconsortium.org: